Ranbaxy launches chewable cefaclor

- Last updated on GMT

Related tags: Penicillin

The US subsidiary of India's Ranbaxy has launched a cephalosporin
antibiotic in a chewable tablet formulation designed to be easier
to take by patients who struggle with tablets or capsules.

Raniclor (cefaclor) is the first and only cephalosporin chewable on the market, and is taken twice or three times a day, depending on the use. It is indicated for the treatment of bacterial infections, including otitis media, lower respiratory tract infections, pharyngitis/tonsillitis, and urinary tract infections.

Ranbaxy said that the formulation challenge with the new product was to develop a chewable version of the antibiotic that was palatable and did not require refrigeration. The branded version of the antibiotic, sold by originator Eli Lilly, is only available in oral suspension and capsule forms.

The launch fits with Ranbaxy's strategy of offering a stable of branded generic products that offer improvements over existing treatment modalities. Cefaclor was once Lilly's biggest product with global sales of around a billion dollars a year in the early 1990s, but recent data from IMS reveal that the US market for the antibiotic has now contracted to $16.7 million (€13.8m) in 2003.

Raniclor is available in 125mg, 187mg, 250mg, and 375mg strengths.

Related topics: Ingredients, Delivery technologies

Related news

Show more

Related products

show more

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Follow us


View more